Artwork

Kandungan disediakan oleh Talking About Tumors. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Talking About Tumors atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

03_01 The era of immune checkpoint inhibitors

22:59
 
Kongsi
 

Manage episode 359156863 series 3335024
Kandungan disediakan oleh Talking About Tumors. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Talking About Tumors atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

1. History of Immunotherapy
2. Modern immune checkpoint inhibitors (ICIs)
3. Unique considerations with ICIs
4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episod

Artwork
iconKongsi
 
Manage episode 359156863 series 3335024
Kandungan disediakan oleh Talking About Tumors. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Talking About Tumors atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

1. History of Immunotherapy
2. Modern immune checkpoint inhibitors (ICIs)
3. Unique considerations with ICIs
4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas
Dengar rancangan ini semasa anda meneroka
Main